# **BMJ Open** Prevalence of delirium in German nursing homes: protocol for a crosssectional study

Jonas Dörner <sup>(1)</sup>, <sup>1,2</sup> Alexandre Houdelet-Oertel, <sup>1,2</sup> Zafer Arslan, <sup>3</sup> Romy Lauer, <sup>4</sup> Ina Otte, <sup>4</sup> Horst Christian Vollmar <sup>(1)</sup>, <sup>4</sup> Petra Thürmann <sup>(1)</sup>, <sup>3</sup> Rebecca Palm <sup>(1)</sup>, <sup>5</sup> Bernhard Holle <sup>1,2</sup>

### ABSTRACT

Introduction Delirium is a neuropathological syndrome that is associated with several negative outcomes. Nursing home residents are vulnerable to developing delirium. Valid prevalence data and associated factors are not yet available for Germany. Therefore, the aim of the prevalence study of the DeliA project (Delirium in Nursing Homes) is to assess the prevalence of delirium and its associated factors in 750 nursing home residents.

Methods and analysis Trained registered nurses from each participating nursing home will collect the data in a multicentre cross-sectional study. The inclusion criteria for residents are valid informed consent, age ≥65 years and sufficient language skills. The exclusion criteria are aphasia, coma, deafness or end-of-life status. The 4 'A's Test will be used as the primary measurement. Delirium motor subtypes will be determined using the Delirium Motor Subtype Scale. Covariables for associated factors, including functional impairments, pain, cognitive status and nutritional status, are assessed through standardised measurements. Moreover, data such as prescribed drugs or medical diagnosis, hearing impairment or falls will be assessed from the nursing records. Furthermore, the Drug Burden Index will be calculated, and associated factors will be determined using a logistic regression model. The period for data collection in participating nursing homes is planned for 2 consecutive weeks in April 2024. Ethics and dissemination This study was approved by

the Ethics Committee of Witten/Herdecke University (no. 82/2023). Findings will be published in peer-reviewed journals and presented at conferences.

Registration https://osf.io/xkfvh/ (DOI 10.17605/0SF.IO/ XKFVH).

To cite: Dörner J, Houdelet-Oertel A. Arslan Z. et al. Prevalence of delirium in German nursing homes: protocol for a crosssectional study. BMJ Open 2025;15:e087482. doi:10.1136/ bmjopen-2024-087482

 Prepublication history for this paper is available online. To view these files, please visit the journal online (https://doi. org/10.1136/bmjopen-2024-087482).

JD and AH-O are joint first authors.

Received 11 April 2024 Accepted 12 December 2024

#### Check for updates

C Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights

and permissions. Published by BMJ Group. For numbered affiliations see

end of article. **Correspondence to** 

Mr Bernhard Holle: Bernhard.Holle@dzne.de

#### INTRODUCTION

Delirium is a neuropathological syndrome that negatively affects perception, consciousness and cognitive performance. It derives within short time spans, and the course of the syndrome often fluctuates.<sup>1</sup> The genesis of delirium is multifactorial.<sup>2-4</sup> Predisposing and precipitating risk factors include advanced age, dementia, functional impairment, malnutrition, infections<sup>5</sup> or polypharmacy as well as a high anticholinergic

# STRENGTHS AND LIMITATIONS OF THIS STUDY

- $\Rightarrow$  The expected sample size will be one of the largest worldwide using primary research data compared with prevalence studies already conducted in nursing homes.
- $\Rightarrow$  Planned data collection from 750 residents, including a maximum of 15 randomly selected residents in each participating nursing home.
- $\Rightarrow$  Use of the 4 'A' Test, a well-validated tool for delirium screening, through trained nursing staff for each nursing home.
- $\Rightarrow$  The gold standard, the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR), will not be used to assess delirium in nursing home residents

Protected by copyright, including for uses related to text and and sedative load, as expressed in the Drug Burden Index.<sup>6</sup> The relationship between da pain medication and pain management and delirium is unclear.<sup>4</sup> Delirium is associated with several negative outcomes, such as prolonged hospital stays, risk of institutional placement, incomplete functional recovery, dementia, morbidity and mortality.<sup>7–9</sup> More-over, falls, pressure ulcers and dehydration are associated with negative events if delirium **g** is present.<sup>10 11</sup> At the same time, delirium is a major cause of distress for patients, caregivers and healthcare providers.<sup>12–15</sup>

For persons at risk, it is recommended to observe them on a daily basis to recognise changes or fluctuations indicating delirium. Informants can be carers or relatives. If indicators of a delirium are recognised, appropriate g tools should be used to assess the delirium.<sup>16</sup>

Nursing home residents in particular have a high risk of delirium because they have multiple risk factors.<sup>17</sup><sup>18</sup> At the same time, delirium and its symptoms are often underrecognised in nursing home residents.<sup>19</sup>

Literature reviews have demonstrated that, depending on different populations and study designs, there is high heterogeneity in the prevalence of delirium, ranging



from 1% to 70%, in nursing homes.<sup>20 21</sup> Studies with valid measurements to collect primary data for the estimation of delirium prevalence and associated factors in German nursing homes are not yet known. The aim of the proposed study is to assess the prevalence of delirium and its associated factors through a multicentre crosssectional study. The following research questions are guiding the study:

- 1. What is the prevalence of delirium and its subtypes in residents of German nursing homes?
- 2. Which factors are associated with the occurrence of delirium in residents of German nursing homes?

### **METHODS AND ANALYSIS** Study design

The prevalence and associated factors are estimated within a multicentre cross-sectional observational study in nursing homes in the federal state of North Rhine-Westphalia in Germany. The study is part of the DeliA (Delirium in Nursing Homes) consortium project (https://delia.info).<sup>22</sup> The data collection takes place from 15 April to 28 April 2024.

# Patient and public involvement

The residents of the nursing homes were not included in the design of the study. There are also no plans to involve residents in the further steps of the study.

### Setting and participants

#### Cluster level

All nursing homes in the federal state of North Rhine-Westphalia in Germany according to paragraph 71, (2) SGB XI<sup>23</sup> that have at least 50 residents and do not exclusively care for specific groups of residents (eg, residents in a coma) can participate.

#### **Resident level**

Residents ≥65 years who receive long-term care can participate if they understand German sufficiently to answer the questions of the rater. To participate in the study, residents or their legal representatives must sign an informed consent form. Residents with end-of-life status, in a coma, with deafness (despite aids) or aphasia will be excluded.

#### **Nurse level**

Registered nurses who participate as raters in the DeliA prevalence study need to have at least 3 years of professional education, which is standard in Germany. They are responsible for the recruitment of participants and data collection. Before the empirical phase starts, a 1-day education session is mandatory, with knowledge transfer related to delirium and study management.

#### Recruitment

The objective is to recruit 50 nursing homes. Potential facilities are recruited via e-mail, telephone and trade journals. The start of the recruitment phase of the nursing homes was September 2023. In each nursing home, the

aim is to recruit 15 residents by random selection. The selection phase began in February 2024 and will continue until the start of the data collection period in April 2024. Each participating nursing home creates a fixed list, numbered in ascending order, of all long-term care residents living in the nursing home on a reference day. This forms the starting point for the selection procedure of potential participants within the study. The research team is informed only about the number of residents without identifiable information. At the research centre, these numbers will be randomly listed for each nursing home. Subsequently, the first 30 random numbers will then be added to a recruitment list and sent back to the nursing home. The rater then assigns the residents on the recruitment list according to their numbering and starts recruitment with the individual at the top of the list, proceeding to the individual at the bottom. If there are reasons for exclusion, a resident does not want to participate or is no longer available (eg, due to removal or hospitalisation), the next resident on the list is checked for eligibility and asked to participate until 15 eligible residents in each nursing home agree to participate. If the initial 30 random numbers are not sufficient for the recruitment use process, an additional 10 numbers can be requested from the study team multiple times until all numbers from a

Brocess, an additional 10 numbers can be requested from the study team multiple times until all numbers from an unsing home have been sent. The raters of each participating nursing home are responsible for informing the study and obtaining informed consent.
Data collection
For the data collection, registered nurses from participating nursing homes recruit residents and collect the study. The data collection starts when the signed informed consent of the participant is available.
Educational training
The DeliA study team developed a 1-day training for the training includes three modules: (1) study management (random selection procedure, handling of the raters. The training will be conducted in four different for the raining includes three modules: (1) study management (random selection procedure, handling of all measurements for data collection and especially for the primary obtaining informed consent, handling of all measurements for data collection and especially for the primary obtaining informed consent, handling of all measurements of data security issues and transfer of collected data to the study team); (2) medical knowledge transfer securities and differential diagnoses of dementia, depression and psychosis) and (3) pharmacotherapeutic knowledge (neurophysiological effect of drugs and groups of drugs and differential diagnoses of dementia, depression, additional online training or in-house training will be offered through the study team. Furthermore, the raters will be given a training manual that describes the processes of the study and contains instructions on how to carry and other study and contains instructions on how to carry and and and contains instructions on how to carry and the study team. Furthermore, the raters will be given a training manual that describes the processes of the study and contains instructions on how to carry and the study team of the planed training seconds on how to carry and the study team. Furthermore, the raters will be given a training man

out the measurements. In addition, the study team can be contacted via telephone or email for questions throughout the entire duration of the study. The training will be conducted by members of the research team, consisting of a general practitioner with several years of clinical experience in the treatment of nursing home residents, a pharmacist and a team of nursing scientists who also possess clinical expertise in managing delirium.

# Process of data collection

The data will be collected using standardised forms via 'Paper & Pencil'; data on medication will be taken from the records of the nursing home residents (copies or printouts). The raters prepare themselves for the data collection in terms of analysing the nursing records and exchange with nurses who are most familiar with the participating residents to obtain all the necessary information for successful data collection. The data collection period is planned in two phases. The first phase begins with measurements based on the assessments of the 15 participating residents in each nursing home (primary measure delirium and delirium subtype, secondary measures functional impairments, pain, cognitive impairments, neuropsychiatric symptoms, malnutrition). During the first 5 days of the data collection period, the raters can carry out the measurements at any time. If the primary measure is assessed for a participant, all further assessments need to be carried out immediately afterwards. When measurements are assessed, the second phase of data collection takes place. The raters then collect data from the residents' nursing records. If medication plans cannot be copied or printed, the information is also collected using standardised forms ('Paper & Pencil'). Only data from the nursing records that were recorded up to the day on which the assessment was performed are considered.

To describe the characteristics of the raters, sociodemographic data will be assessed.

To describe the characteristics of the participating nursing homes, corresponding structural data such as sponsorship or number of living areas of the facilities will be collected.

# **Primary measures**

Delirium will be assessed using the 4-'A's Test (4AT).<sup>24</sup> The 4AT is proxy-rated and consists of four items—(1)Alertness, (2) Abbreviated Mental Test-4,<sup>25</sup> (3) Attention (using Month Backwards Test)<sup>26</sup> and (4) Acute change or fluctuating course-and creates a sum score of 0-12. A score of 0 indicates that delirium or cognitive impairment is unlikely (but still possible), a score of 1-3 points indicates possible moderate to severe cognitive impairment, and a score of 4 points or above indicates possible delirium.<sup>24</sup> The measurement showed good diagnostic results with a pooled specificity of 88% and a pooled sensitivity of 88%.<sup>27</sup>

If the 4AT screening is positive  $(\geq 4)$ , the Delirium Motor Subtype Scale (DMSS) will be applied.<sup>28</sup> The DMSS is <page-header><page-header><text><section-header><text><text><text><text>

The cut-off that has proven to be most suitable for identifying people with dementia syndrome in nursing homes is≥3 points.<sup>36</sup>

Neuropsychiatric symptoms will be assessed using the Neuropsychiatric Inventory-Questionnaire (NPI-O),<sup>37</sup> a short form of the Neuropsychiatric Inventory.<sup>38</sup> The survey with the NPI-Q is a proxy-rated measurement and consists of 12 items: (1) Delusions, (2) Hallucinations, (3) Agitation/aggression, (4) Dysphoria/depression, (5) Anxiety, (6) Euphoria/elation, (7) Apathy/indifference, (8) Disinhibition, (9) Irritability/lability, (10) Aberrant motor behaviours, (11) Night-time behavioural disturbances and (12) Appetite/ eating disturbances. The rating refers to the presence of symptoms. The severity of the symptoms can be scored between 0 and 36 points (total score).<sup>37</sup>

The nutritional status of participants will be assessed using the revised short form of the validated Mini Nutritional Assessment (MNA)<sup>39</sup>—the MNA short form (MNA-SF).<sup>40</sup> The revised short form has seven items: (1) Has food intake declined over the past 3 months due to loss of appetite, digestive problems, chewing or swallowing difficulties? (2) Weight loss during the last 3 months, (3) Mobility, (4) Have you suffered psychological stress or acute disease in the past 3 months? (5) Neuropsychological problems, (6) Body Mass Index (BMI) (weight in kg)/(height in m<sup>2</sup>) and (7) Calf circumference (CC) in cm. The MNA-SF scale ranges from 0 to 14 points (12-14 points: normal nutritional status, 8-11 points: risk of malnutrition, 0–7 points: malnutrition).<sup>40</sup> To compare the results across all nursing homes more accurately, we decided to assess only CC rather than BMI.

The raters will be collecting further information, such as age, sex or medical diagnoses, based on the available nursing records of the participating residents (table 1).

BMJ Open: first published as 10.1136/bmjopen-2024-087482 on 15 January 2025. Downloaded from http://bmjopen.bmj.com/ on June 14, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) data mining, AI training, and similar technologies

đ

text

In addition, data on each prescribed medication will be recorded based on the items of the German Federal Standardised Medication Plan<sup>41</sup> (table 2).

# Bias

Residents in the facilities will be recruited on the basis of a random sample, which avoids a greater selection bias. However, bias may arise during the recruitment phase in connection with the recruitment list, for example, due to incorrect allocation of residents to the recruitment list or a non-chronological selection process of residents. To minimise this bias, the raters were trained in the use of the list (see educational training). Furthermore, the research team will provide the recruitment list with the random numbers, and only the first 30 numbers on each list will be sent back to each nursing home. The risk of bias is, therefore, considered low. Further bias can arise through in the assessment of the residents by the raters themselves. The evaluation of very well-known residents in nursing homes may lead raters to make subjective judgements during data collection. However, training for the rater in the correct use of the assessments will also help to reduce for uses related the scope for discretion and thus minimise potential observer bias.

# Sample size calculation

The sample size calculation was conducted in accordance with Bujang *et al*,  $^{42}$  who proposed estimating the prevalence with logistic regression models including covariables. The calculation was undertaken for a final regression model with up to 11 relevant covariables. This leads to a necessary sample size of n=650 residents for the present study. To compensate for potential drop-out,

Table 1         Nursing records data		
Definition of items	Number of items	Empirical measure
Sex of resident	1	Female/male or non-binary
Year of birth	1	Date (year)
Move-in date in actual nursing home	1	Date (month/day/year)
Family status of resident	1	Single/married/divorced/widowed or other (free-text
Care level according to Long Term Care Insurance SGB XI	1	No degree of care/degree of care: 1, 2, 3, 4 or 5
Stationary hospital stay(s) of resident in the past 3 months	1	Yes*/no *Period of each hospital stay (free-text)
Vision impairment and hearing impairment (with hearing aid)	2	Yes/no
Fall(s) in the past 3 months in nursing home	1	Yes/no/unable to specify
Measures to deprive of freedom in the past 4 weeks in nursing home (multiple selections possible)	1	Bed rails/belt restraint/other (free-text)/none/unable to specify
Presence of feeding tube	1	PEG/PEJ/other (free-text)/none
Presence of urinary catheter	1	Suprapubic/transurethral/none
Infectious disease(s) with date of onset	1	Free text
Selected medical diagnoses (multiple selection possible)	1	Dementia/depression/Parkinson and/or hypertension
All medical diagnoses with ICD code (if available)	1	Free-text

ICD, International Classification of Diseases; PEG, percutaneous endoscopic gastrostomy; PEJ, percutaneous endoscopic jejunostomy; SGB XI, Sozialgesetzbuch XI - Pflegeversicherung.

Table 2         Medication data based on nursing records			
Data for each prescribed medication	Number of items	Empirical measure	
Drug and trade name	2	Free-text	
Strength and unit	1	Strength (free-text) and µg/mg/g/mL/dL or I.E.	
Form	1	Tablet/Sachet/Capsule/Spray/Powder/Paste/Ointment/Cream/ Gel/Juice/Suppository/Drops/Solution/Liquid/Chewable tablet/ Effervescent tablet/Plaster/Probe or Injection	
Interval of intake (multiple selection possible)	1	Morning/midday/evening and/or night	
Other interval of intake	1	Before eating/after eating/hourly/daily/weekly/monthly/when required/ one time/two times/three times/four times/every 2 weeks/every 3 weeks/ one time a week/two times a week/three times a week /every 2 days/every 3 days/every 4 days/every 2 hours/every 4 hours/every 6 hours/every 8 hours/every 12 hours/two times a day/three times a day or four times a day	
Start of medication	1	Date (free-text)	
On-demand medication	1	Yes/no	

an additional 100 residents will be recruited. To reduce possible cluster effects, data from a maximum of 15 residents per participating nursing home will be collected. This means that participation is needed from at least 50 nursing homes for the prevalence study.

#### Statistical analysis

Descriptive analysis for continuous variables will be based on the calculation of the mean (±) and SD for normally distributed data or the median and IQR for non-parametrically distributed data. Categorical variables will be calculated as absolute numbers (n) and percentages (%). For the respective variables, appropriate parametric comparisons will be made between the residents with delirium and residents without delirium to determine significant differences. If the data are not normally distributed, non-parametric tests will be used.

For continuous variables such as the PSMS score and NRS score, the independent t-test or the Mann-Whitney U test will be used. Categorical variables, such as vision and hearing impairment, will be compared between the two groups using the  $\chi^2$  test or Fisher's exact test, depending on how many observations were made in each category.

Univariate regression analysis will be used to evaluate the associations between the variables and delirium.

Variables identified as significant will be included in a multivariable regression analysis to determine whether there is an independent association between delirium and these variables. If suitable, additional variables will be selected based on research results from similar studies. The significance level for the results will be set at 95% (p<0.05).

Further variables will be determined based on the medication data. The German Drug Burden Index will be calculated according to the Drug Burden Index developed by Hilmer et al,43 taking drug dosages into account and applying the list of Kiesel *et al*<sup>44</sup> for the German drug market as described recently.<sup>45</sup> In addition, use of potentially inappropriate medications according to the

Protected by copyright, includ PRISCUS (PIM) list version V.2.0<sup>46</sup> will be assessed. To record polypharmacy ( $\geq 5$  pharmaceuticals), the number of medications for each resident will be computed. For ð this calculation, regular medication as well as medication r uses related as needed will be considered.

# DISCUSSION

ð This will be the first study to present valid prevalence data e regarding delirium and associated factors in German nursing homes. Moreover, the expected sample size will be one of the largest worldwide compared with prevalence studies already conducted in nursing homes.<sup>47–50</sup> A major strength of this study is that a maximum of 15 residents  $\Xi$ in each nursing home will be randomly selected. This may reduce the influence of organisational-specific and ≥ population-specific variables. Furthermore, a strength is the use of validated assessments as primary measures and the comprehensive training of registered nurses as raters ŋg, in the participating nursing homes. This ensures that the data collection will be conducted by rater who are familiar with the environment, residents and colleagues. This can support the data collection.

To our knowledge, this will be the first study to analyse the association between DBI scores and delirium in German nursing home residents. Previous studies across different settings revealed polypharmacy as a relevant factor.<sup>6 43 51</sup> As the DBI reflects the anticholinergic and sedative properties of drugs, this measure should be more **g** specific than simply counting the number of drugs used. Katipoglu *et al*<sup>b</sup> recently demonstrated an association between DBI and delirium in ambulatory patients with dementia.

As a limitation, the Diagnostic and Statistical Manual of Mental Disorders V (DSM-V),<sup>1</sup> the gold standard for delirium diagnosis, will not be used. Instead, the 4AT was chosen because of the good psychometric properties<sup>27</sup> and fast and easy administration. However, the 4AT may overestimate delirium in people with dementia because of overlapping symptoms.<sup>50</sup> But currently, there is no instrument that is superior to the 4AT in terms of practicability and validity in this cohort. Furthermore, fluctuating symptoms are common for delirium; therefore there is a risk that delirium patients will not be identified.<sup>52</sup> In addition, the selected study design involved only a single delirium assessment for each participant at a specific time, which makes identification even more difficult. However, the 4AT allows measurement of fluctuating symptoms using evidence from anamnesis. In addition, the nursing home setting promotes an existing information history from residents. Another limitation is, that with the design of a prevalence study, delirium episodes that do not occur at the time point of assessment, are not detected. This is why prevalence studies may under-report delirium.

With our results, we expect to provide new evidence on delirium for the development of interventions for the nursing home setting and for the improvement of professional care.

#### **Ethics approval and dissemination**

The Ethics Committee of Witten/Herdecke University approved this study (no. 82/2023). Participants will receive written and oral information about the study from the nurses in the nursing homes. To participate in the study, written informed consent is necessary for residents. From residents with a legal representative, a written informed consent of them is needed to participate. Nurses who serve as raters also have to sign the informed consent. Information about the option to withdraw consent at any time will be given. The authors confirm that all steps in the study will be performed in accordance with the regulations of the Declaration of Helsinki.

The findings of the study will be disseminated in peerreviewed publications in journals and will be presented at conferences.

#### **Author affiliations**

<sup>1</sup>German Centre for Neurodegenerative Diseases (DZNE), Witten, Nordrhein-Westfalen, Germany

<sup>2</sup>School of Nursing Science, Faculty of Health, Witten/Herdecke University, Witten, Nordrhein-Westfalen, Germany

<sup>3</sup>Department of Medicine, Chair of Clinical Pharmacology, Faculty of Health, Witten/ Herdecke University, Witten, Nordrhein-Westfalen, Germany

<sup>4</sup>Institute of General Practice and Family Medicine (AM RUB), Ruhr University

Bochum, Bochum, Nordrhein-Westfalen, Germany

<sup>5</sup>School VI—School of Medicine and Health Sciences, Carl von Ossietzky Universität Oldenburg, Oldenburg, Niedersachsen, Germany

X Horst Christian Vollmar @@hcvollmar and Rebecca Palm @RebeccaPalm4

**Contributors** Study design (methods and analysis): AH-0, JD, ZA, RL, IO, HCV, PT, RP, BH. First draft of the manuscript: JD, AH-0, ZA, RL, IO, HCV, PT, RP, BH. Manuscript preparation: JD, AH-0, ZA, RL, IO, HCV, PT, RP, BH. Responsible for overall content as guarantor: BH.

**Funding** The study is funded by the Innovation Fund of the Federal Joint Committee (grant number 01VSF20003).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer-reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### **ORCID** iDs

Jonas Dörner http://orcid.org/0000-0002-7631-9881 Horst Christian Vollmar http://orcid.org/0000-0002-0117-7188 Petra Thürmann http://orcid.org/0000-0001-9724-1422 Rebecca Palm http://orcid.org/0000-0002-4910-8413 Bernhard Holle http://orcid.org/0000-0003-2549-7765

#### REFERENCES

- 1 American Psychiatric Association: Diagnostic and statistical manual of mental disorders. 2022.
- 2 Iglseder B, Frühwald T, Jagsch C. Delirium in geriatric patients. *Wien Med Wochenschr* 2022;172:114–21.
- 3 Addesi D, Maio R, Smirne N, et al. Prevalence of Delirium in a Population of Elderly Outpatients with Dementia: A Retrospective Study. J Alzheimers Dis 2018;61:251–7.
- 4 Wilson JE, Mart MF, Cunningham C, et al. Ely EW: Delirium. Nat Rev Dis Primers 2020;6:90.
- 5 Ormseth CH, LaHue SC, Oldham MA, *et al.* Predisposing and Precipitating Factors Associated With Delirium: a Systematic Review. *JAMA Netw Open* 2023;6:e2249950.
- 6 Katipoglu B, Demircan SK, Naharci MI. Association of drug burden index with delirium in community-dwelling older adults with dementia: a longitudinal observational study. *Int J Clin Pharm* 2023;45:1267–76.
- 7 Leslie DL, Zhang Y, Holford TR, et al. Premature death associated with delirium at 1-year follow-up. Arch Intern Med 2005;165:1657–62.
- 8 Andrew MK, Freter SH, Rockwood K. Incomplete functional recovery after delirium in elderly people: a prospective cohort study. *BMC Geriatr* 2005;5:5.
- 9 Johansson YA, Bergh I, Ericsson I, et al. Delirium in older hospitalized patients-signs and actions: a retrospective patient record review. BMC Geriatr 2018;18:43.
- 10 Kalivas B, Zhang J, Harper K, et al. The Association between Delirium and In-Hospital Falls: A Cross-Sectional Analysis of a Delirium Screening Program. J Aging Res 2023;2023:1562773.
- 11 Johnson JC. Delirium in the elderly. *Emerg Med Clin North Am* 1990;8:255–65.
- 12 Morandi A, Lucchi E, Turco R, *et al.* Delirium superimposed on dementia: A quantitative and qualitative evaluation of patient experience. *J Psychosom Res* 2015;79:281–7.
- 13 Morandi A, Lucchi E, Turco R, et al. Delirium superimposed on dementia: A quantitative and qualitative evaluation of informal caregivers and health care staff experience. J Psychosom Res 2015;79:272–80.
- 14 Williams ST, Dhesi JK, Partridge JSL. Distress in delirium: causes, assessment and management. *Eur Geriatr Med* 2020;11:63–70.
- 15 Bianchi LA, Harris R, Fitzpatrick JM. Barriers to healthcare professionals recognizing and managing delirium in older adults during a hospital stay: A mixed-methods systematic review. J Adv Nurs 2024;80:2672–89.
- 16 NICE: National Institute for Health and Care Excellence: Guidelines. Delirium: Prevention, Diagnosis and Management in Hospital and Long-Term Care. London: National Institute for Health and Care Excellence (NICE), 2023.
- 17 Inouye SK, Westendorp RGJ, Saczynski JS. Delirium in elderly people. *Lancet* 2014;383:911–22.
- 18 Cheung ENM, Benjamin S, Heckman G, et al. Clinical characteristics associated with the onset of delirium among long-term nursing home residents. *BMC Geriatr* 2018;18:39.
- 19 Voyer P, Richard S, Doucet L, *et al*. Detection of delirium by nurses among long-term care residents with dementia. *BMC Nurs* 2008;7:4.
- 20 Komici K, Guerra G, Addona F, *et al.* Delirium in Nursing Home Residents: A Narrative Review. *Healthcare (Basel)* 2022;10:1544.
- 21 de Lange E, Verhaak PFM, van der Meer K. Prevalence, presentation and prognosis of delirium in older people in the population, at home and in long term care: a review. *Int J Geriatr Psychiatry* 2013;28:127–34.

- 22 Delirium in nursing homes. n.d. Available: https://osf.io/xkfvh/
- 23 German Social Code Book XI Social Care. Elftes Buch (XI) -Soziale Pflegeversicherung (artikel 1 des gesetzes vom 26. mai 1994, bgbl. i s. 1014) § 71 pflegeeinrichtungen. n.d. Available: https://www. gesetze-im-internet.de/sgb\_11/\_71.html
- 24 Bellelli G, Morandi A, Davis DHJ, *et al.* Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234 hospitalised older people. *Age Ageing* 2014;43:496–502.
- 25 Schofield I, Stott DJ, Tolson D, et al. Screening for cognitive impairment in older people attending accident and emergency using the 4-item Abbreviated Mental Test. Eur J Emerg Med 2010;17:340–2.
- 26 Katzman R, Brown T, Fuld P, et al. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 1983;140:734–9.
- 27 Tieges Z, Maclullich AMJ, Anand A, *et al.* Diagnostic accuracy of the 4AT for delirium detection in older adults: systematic review and meta-analysis. *Age Ageing* 2021;50:733–43.
- 28 Garcia Nuñez D, Boettger S, Meyer R, et al. Validation and Psychometric Properties of the German Version of the Delirium Motor Subtype Scale (DMSS). Assessment 2019;26:1573–81.
- 29 Lawton MP, Brody EM. Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living. *Gerontologist* 1969;9:179–86.
- 30 Krebs EE, Carey TS, Weinberger M. Accuracy of the pain numeric rating scale as a screening test in primary care. J Gen Intern Med 2007;22:1453–8.
- 31 Jensen MP, Turner JA, Romano JM, *et al*. Comparative reliability and validity of chronic pain intensity measures. *Pain* 1999;83:157–62.
- 32 Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs 2005;14:798–804.
- 33 Basler HD, Hüger D, Kunz R, et al. Beurteilung von Schmerz bei Demenz (BESD). Schmerz 2006;20:519–26.
- 34 Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc 2003;4:9–15.
- 35 Zwakhalen SMG, van der Steen JT, Najim MD. Which score most likely represents pain on the observational PAINAD pain scale for patients with dementia? J Am Med Dir Assoc 2012;13:384–9.
- 36 Köhler L, Weyerer S, Schäufele M. Proxy screening tools improve the recognition of dementia in old-age homes: results of a validation study. *Age Ageing* 2007;36:549–54.
- 37 Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000;12:233–9.

- 38 Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. *Neurology (ECronicon)* 1994;44:2308–14.
- 39 Guigoz Y. The Mini Nutritional Assessment (MNA) review of the literature--What does it tell us? J Nutr Health Aging 2006;10:466–85;

**Open** access

- 40 Kaiser MJ, Bauer JM, Ramsch C, et al. Validation of the Mini Nutritional Assessment short-form (MNA-SF): a practical tool for identification of nutritional status. J Nutr Health Aging 2009;13:782–8.
- 41 Bundeseinheitlicher Medikationsplan Muster (German standardised Medication Plan - Example). n.d. Available: https://www.kbv.de/ media/sp/Medikationsplan\_Beispiel\_2023.pdf
- 42 Bujang MA, Sa'at N, Sidik TMITAB, et al. Sample Size Guidelines for Logistic Regression from Observational Studies with Large Population: Emphasis on the Accuracy Between Statistics and Parameters Based on Real Life Clinical Data. *Malays J Med Sci* 2018;25:122–30.
- 43 Hilmer SN. Calculating and using the drug burden index score in research and practice. *Expert Rev Clin Pharmacol* 2018;11:1053–5.
- 44 Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. *BMC Geriatr* 2018;18:239.
- 45 Dinh TS, Meid AD, Rudolf H, *et al.* Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model. *PLoS One* 2023;18:e0280907.
- 46 Mann NK, Mathes T, Sönnichsen A, et al. Potentially Inadequate Medications in the Elderly: PRISCUS 2.0. Dtsch Arztebl Int 2023;120:3–10.
- 47 Sabbe K, van der Mast R, Dilles T, et al. The prevalence of delirium in Belgian nursing homes: a cross-sectional evaluation. *BMC Geriatr* 2021;21:634.
- 48 McCusker J, Cole MG, Voyer P, et al. Prevalence and incidence of delirium in long-term care. Int J Geriat Psychiatry 2011;26:1152–61.
- 49 Sandberg O, Gustafson Y, Brännström B, et al. Prevalence of dementia, delirium and psychiatric symptoms in various care settings for the elderly. Scand J Soc Med 1998;26:56–62.
- 50 Morichi V, Fedecostante M, Morandi A, et al. A Point Prevalence Study of Delirium in Italian Nursing Homes. Dement Geriatr Cogn Disord 2018;46:27–41.
- 51 Kurisu K, Miyabe D, Furukawa Y, et al. Association between polypharmacy and the persistence of delirium: a retrospective cohort study. *Biopsychosoc Med* 2020;14:25.
- 52 Voyer P, Richard S, McCusker J, *et al.* Detection of delirium and its symptoms by nurses working in a long term care facility. *J Am Med Dir Assoc* 2012;13:264–71.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies